OBJECTIVES. Although bronchiolitis is the leading cause of hospitalization for infants, there are limited data describing the epidemiology of bronchiolitis hospitalizations, and the associated cost is unknown. Our objective was to determine nationally representative estimates of the frequency of bronchiolitis hospitalizations and its associated costs.
B
RONCHIOLITIS IS THE leading cause of hospitalization for infants Ͻ1 year of age. [1] [2] [3] [4] [5] Respiratory syncytial virus (RSV), the most common cause of bronchiolitis, affects almost all children by the age of 2 years. 6 Although hospitalization costs for bronchiolitis are presumed to be high, previous research has focused on RSV bronchiolitis instead of bronchiolitis as a clinical diagnosis. In addition, there are no recent epidemiological data on bronchiolitis hospitalizations among children Ͻ2 years. 5 Estimating bronchiolitis hospitalization costs from RSV-related bronchiolitis may underestimate the true cost of bronchiolitis hospitalizations. Although RSV infection is the most common cause of bronchiolitis, [2] [3] [4] many other infectious agents cause bronchiolitis, including parainfluenza viruses, influenza virus, adenoviruses, and Ն4 other infectious agents. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In addition, previous RSV hospitalization expenditure estimates included all of the RSV-related diagnoses, including RSV-associated pneumonia, and these studies reported hospital charges as opposed to costs based on hospital-specific cost/charge ratios. 2, 18, 19 Lastly, there are several articles reporting hospitalization expenditures because of bronchiolitis hospitalizations in other countries and some single-site studies but none that are representative of all US hospitalizations. [20] [21] [22] [23] [24] [25] [26] [27] [28] Using the Health Care Utilization Project (HCUP), Nationwide Inpatient Sample (NIS) database, we investigated the number of US hospitalizations and associated costs for bronchiolitis from 2002. Estimates were calculated for all of the visits in which bronchiolitis was one of the diagnoses, bronchiolitis was a primary diagnosis only, and then subsets of bronchiolitis hospitalizations according to the presence (or absence) of pneumonia or asthma. Finally, we calculated age-specific estimates of bronchiolitis cost.
PATIENTS AND METHODS

Study Population
The 2002 HCUP-NIS is a federal-state-industry data system funded by the Agency for Healthcare Research and Quality. The HCUP-NIS is a stratified random sample of US community hospitals, defined as all of the nonfederal, short-term, general, and other specialty hospitals, excluding hospital units of institutions. 29, 30 This crosssectional survey is the largest all-payer inpatient care database that is publicly available in the United States, and it is the only national hospital database containing charge information on all patients. Analysis of the HCUP data set was approved by the human research committee.
Study Protocol
The 2002 NIS data were drawn from 35 participating states. A sampling frame of 3570 hospitals was stratified by geographic region, ownership control, teaching status, and bed size. Up to 20% of hospitals were randomly selected from within each stratum. Patient level clinical and resource use information typically available in a discharge abstract were included for all of the discharges from selected hospitals for the sample year. The final sample included 7 853 982 discharges from 995 hospitals.
Measurements and Patients
Each discharge abstract included age, gender, race/ethnicity, primary payer, admission source, length of stay, disposition, and Յ15 procedures and Յ15 discharge diagnoses. Procedures and diagnoses were available using both International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes and the Clinical Classifications Software (CCS), which is a methodology developed by the Agency for Healthcare Research and Quality to group International Classification of Diseases, Ninth Revision (ICD-9) codes into clinically sensible and mutually exclusive categories. Because the CCS system grouped bronchiolitis and bronchitis into one code (CCS code 125), we used ICD-9-CM code 466.1 in any of the 15 diagnoses fields to identify cases. We examined the most common procedures performed using the ICD-9-CM procedure codes. A portion of the analysis excluded hospitalizations because of routine births. These were identified using CCS code 218 ("liveborn") in the first field. We also identified bronchiolitis cases with a codiagnosis of pneumonia (CCS code 122) and asthma (CCS code 128). When bronchiolitis was not the primary diagnosis, pneumonia or asthma was the primary diagnosis for ϳ70% of cases. Bronchiolitis is a clinical diagnosis, and as a result, there will be practice variation diagnosing bronchiolitis, potential difficulty distinguishing clinically between bronchiolitis and asthma in children Ͻ 2 years, and an overlap with pneumonia. Case subjects were identified when bronchiolitis was the primary diagnosis or, for the purposes of analysis, when bronchiolitis was included in any of the 15 diagnoses fields. Only children Ͻ 2 years were eligible for inclusion.
Total costs were estimated by applying the HCUP cost/charge ratio (CCR) files. Each file contains hospitalspecific CCRs based on all-payer inpatient cost for nearly every hospital in the corresponding NIS or State Inpatient Database databases. Cost information was obtained from the hospital accounting reports collected by the Centers for Medicare and Medicaid Services. Because of incomplete hospital CCR data, cases without hospitalspecific CCRs were excluded, and data were appropriately reweighted to analyze costs.
Data Analysis
We determined point estimates and 95% confidence intervals (CIs) for patient characteristics, charges, and costs for US bronchiolitis-related discharges. We also examined the frequency of procedures and associated diagnoses. Nationally representative estimates were determined using NIS-assigned discharge weights appropriate for the 20% subsample, which adjusted for the probability of selection. Data are presented with number of observations for the 20% subsample and the corresponding weighted totals representative of all discharges in the United States.
Age was studied as a dichotomous variable: Ͻ1 and Ն1 to Ͻ 2 years (hereafter referred to as age 1 year). Binomial and categorical variables were analyzed using weighted 2 . Differences in means were evaluated using a t statistic appropriate for survey data. A multivariate linear regression of total costs was performed with predefined demographic, administrative, and treatment characteristics. All of the analyses were performed using appropriate survey commands to account for the stratified, 2-stage sampling frame. Although cost data were skewed, we did not transform the data because of the very large size of the data set. Based on the central limit theorem, in a very large data set, the distribution of an average tends to be normal, even when the distribution from which the average is computed is decidedly nonnormal. 31 All of the P values are 2-sided, with P Ͻ .05 considered statistically significant. Data analysis was performed using Stata 9.0. (Stata Corp, College Station, TX).
RESULTS
In 2002, there were an estimated 149 000 (95% CI: 130 000 to 167 000) hospitalizations for bronchiolitis. This accounted for 3.0% (95% CI: 2.7% to 3.3%) of all hospitalizations for children Ͻ2 years and 2.7% (95% CI: 2.4% to 3.0%) for those Ͻ1 year. After excluding all routine births, bronchiolitis hospitalizations accounted for 18.8% (95% CI: 17.4% to 20.2%) of all children Ͻ2 years and 21.1% (95% CI: 19.3% to 22.9%) of children Ͻ1 year. As shown in Table 1 , the total cost of all of the bronchiolitis hospitalizations was $543 million (95% CI: $439 million to $648 million), which corresponded with total charges of $1.4 billion (95% CI: $1.1 billion to $1.7 billion). Children Ͻ1 year accounted for most of this annual cost (Table 1) . The cost for the subset of patients with a primary diagnosis of bronchiolitis was $390 million (95% CI: $321 million to $459 million).
Pneumonia was a codiagnosis in 16% (95% CI: 14% to 17%) of case subjects, and asthma was a codiagnosis in 11% (95% CI: 9% to 12%). Excluding children with a codiagnosis of pneumonia or asthma lowered the annual cost, but it still exceeded $366 million per year. Mean cost for a bronchiolitis hospitalization with a codiagnosis of pneumonia was $6191 vs a mean of $3376 when a codiagnosis of pneumonia was absent (P Ͻ .001). The mean cost per bronchiolitis hospitalization with asthma was similar when a codiagnosis of asthma was absent ($3662 vs $3816 with asthma and without asthma, respectively; P ϭ .54). Table 1 shows total cost, mean cost per hospitalization, and mean cost per day for several groups of bronchiolitis patients. Table 2 shows demographic characteristics for bronchiolitis patients. Approximately 85% of patients were children Ͻ1 year. Patients were more likely to be boys than girls (rate per 1000 US population age Ͻ2 years: 21 vs 16; P Ͻ .05). Almost 40% of all children with bronchiolitis were nonwhite, with a population rate higher than that of white non-Hispanics (17 vs 11; P Ͻ .05). There were no significant regional differences. More than 78% of hospitalizations were in urban hospitals. Mean length of stay (LOS) was 3.3 days overall and differed significantly between children Ͻ1 and age 1 year (3.4 vs 2.6 days, respectively; P Ͻ .01).
The majority of patients had Medicaid (58%; 95% CI: 55% to 61%) followed by private insurance (37%; 95% CI: 34% to 40%). Almost all of the patients were discharged from the hospital (96%), with only 2% transferred to a short-term facility and 1.3% having home health care. Five of the 6258 children died in the hospital (number too small to provide stable estimates).
The 3 most common procedures recorded were respiratory medication given by a nebulizer (6.4%; 95% CI: 2.0% to 8.2%), lumbar puncture (4.0%; 95% CI: 3.2% to 4.9%), and oxygen enrichment (2.4%; 95% CI: 0.2% to 4.6%). The top 3 procedures were the same whether or not a codiagnosis of pneumonia or asthma was present (data not shown). Table 3 shows multivariate regression results for predictors of total costs. Model 1, which does not include LOS, demonstrates that the mean cost per hospitalization was higher for younger children, boys, and patients in urban teaching hospitals. Patients who received lum- bar puncture or mechanical ventilation had a higher mean cost than those not receiving those procedures ($2117 and $21 469 higher, respectively). Having a codiagnosis of pneumonia raised the mean cost by $1781 (P Ͻ .001). In model 2, controlling for LOS, being older was more expensive, but neither having procedures nor being female predicted cost when LOS was included in the model. Having a codiagnosis of pneumonia was only a borderline significant predictor of higher cost (P ϭ .07).
DISCUSSION
This nationally representative study of bronchiolitis hospitalizations identified 149 000 discharges for bronchiolitis in the year 2002. These hospitalizations resulted in annual national direct medical costs of approximately $543 million, which corresponded with total hospital charges of $1.4 billion. When data were limited to bronchiolitis as a primary diagnosis only, hospitalization costs were almost $400 million. Leader et al 2 used the 1997-2000 National Hospital Discharge Survey database linked with the HCUP NIS database to estimate hospital charges among children Ͻ1 year because of a primary diagnosis of RSV (including RSV pneumonia without actual bronchiolitis). The total reported annual charges were $650 million. If these charges are converted to actual costs (using a 2002 ratio provided by the HCUP office, written communication, 2005), the total cost would be approximately $300 million. Stang et al 22 also looked at charges and used the NIS database from 1993. Their criteria for inclusion were children Ͻ1 year with an ICD-9 code of bronchiolitis (466.1) and hospitalization from November through April. Their estimated total hospital charges from the year 1993 (adjusted to 1998 dollars) were between $365 million and $585 million. The actual costs would be considerably smaller. Although we used the same ICD-9 code criteria as Stang et al 22 , they focused on RSV-related bronchiolitis infection only. Comparing estimates from these previous studies with the current study demonstrates that limiting cases to RSV-related diagnoses underestimates the true, total cost of bronchiolitis hospitalizations. Even when we applied the same criteria used previously, and adjusted for inflation, the bronchiolitis costs in our analysis are significantly higher than previous estimates (data not shown).
Mean hospitalization costs were considerably different based on whether a codiagnosis of pneumonia was present. Mean cost per hospitalization for those with a codiagnosis of pneumonia was significantly higher, $6191 vs $3376, for those without a codiagnosis of pneumonia, although this difference seems to be attributable to longer LOS. However, health care providers may unnecessarily order chest radiographs 3, 32 and may overdiagnose pneumonia. 33 Future studies should identify best practices for the identification of children with the codiagnoses of bronchiolitis and pneumonia.
To put the national cost of bronchiolitis in perspective, we examined previous studies on hospitalization costs for other respiratory diseases, such as asthma and cystic fibrosis. One study reported annual costs of asthma hospitalizations in 1990 to be $1.6 billion 34 and another in 1994 to be $2.5 billion. 35 Although these costs are higher than those estimated for bronchiolitis hospitalizations in this study, the asthma costs include all ages, not just those Ͻ2 years. Lieu et al 36 estimated the total costs for cystic fibrosis to be approximately $314 million in 1996. They report that 47% of cystic fibrosis costs were from hospitalizations, making $147 million attributable to inpatient costs. This is much lower than the bronchiolitis costs found in this study.
Younger age, male gender, urban hospital/teaching status, receiving a lumbar puncture or mechanical ventilation, and having a codiagnosis of pneumonia all predicted higher hospitalization cost based on the longer LOS. Younger age and being male are both associated with more severe bronchiolitis. 5, 37, 38 However, when we controlled for LOS, older age became a significant predictor of higher cost. A possible explanation is that older children who require hospitalization for bronchiolitis may have chronic conditions resulting in higher costs, compared with frequently hospitalized, but otherwise healthy Ͻ1-year-olds. However, we looked at all of the codiagnoses for children Ͻ1 year and those 1 year of age, and they were similar, concluding that there may be another reason for the higher costs, a finding that merits additional study.
The study has a few potential limitations. First, the diagnosis of bronchiolitis is clinical. Accordingly, the data are subject to different diagnostic standards across the many US hospitals. We believe that including an inpatient diagnosis of bronchiolitis in any of the 15 fields reduces chances that we are missing true bronchiolitis cases. Second, the HCUP database does not collect race and ethnicity separately, making it difficult to interpret these demographic characteristics for bronchiolitis. Lastly, the HCUP database is useful for overall counts and cost calculations, but medication and imaging data are not available. Therefore, we were unable to analyze usage of antibiotics and chest radiographs and to determine their contribution to the overall cost. Because these represent likely targets for cost reduction, an itemized accounting of inpatient costs merits future study.
CONCLUSIONS
Bronchiolitis hospitalizations consume significant health care resources. According to this analysis of recent, nationally representative data, costs are higher for bronchiolitis hospitalizations than reported previously for RSV-related hospitalizations (including nonbronchiolitis conditions). Children with bronchiolitis and a codiagnosis of pneumonia have more expensive hospitalizations, which is largely because of longer hospital stays. We support efforts to develop evidence-based guidelines for
